Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

Who cannot join

• 1)The patient has previously received anti-tumor therapy (including chemotherapy, radiotherapy, surgery or immunotherapy, etc.) 2) The patient has or is expected to have an obvious risk of esophageal perforation, fistula and massive bleeding; 3) Exclude subjects who have previously suffered from other malignant tumors, unless they have achieved complete elimination at least 5 years before entering the study, and no additional treatment is required or expected during the study period (exceptions include but are not limited to basal or squamous cells) Skin cancer, superficial bladder cancer or carcinoma in situ of prostate, cervix or breast); 4)Subjects with known or suspected active autoimmune diseases. It is allowed to include type I diabetes, hypothyroidism that requires only hormone replacement therapy, skin diseases that do not require systemic treatment (eg, vitiligo, psoriasis, or hair loss), or in the absence of external triggers, it is not expected Subjects with relapsed conditions; 5)Clinically obvious cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction, unstable or severe angina pectoris, coronary artery bypass surgery, congestive heart failure, ventricular arrhythmia requiring medical intervention within 6 months before enrollment 、Left ventricular ejection fraction <50%, or other patients who are not expected to tolerate chemotherapy and radiotherapy; 6)Subjects suffering from conditions requiring systemic treatment with corticosteroids (>10 mg daily prednisone or equivalent dose) or other immunosuppressive drugs within 14 days prior to the administration of the study drug. In the absence of active autoimmune diseases, use inhaled or topical steroids and adrenal replacement steroids with an equivalent dose of> 10 mg daily prednisone; 7)Subjects with symptoms or interstitial lung diseases that may interfere with the detection or treatment of suspected drug-related lung toxicity; 8)Those who have previously received anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti-CTLA-4 antibodies or any other antibodies or drugs that target T cell costimulation or checkpoint pathways as specific targets treatment； 9)All toxicities (except for kidney disease, neuropathy, hearing loss, hair loss, and fatigue) attributable to previous anti-cancer treatments must be restored to level 1 (NCI CTCAE 5th Edition) or baseline before the study drug is administered. Subjects with toxicity that can be attributed to previous anti-cancer treatments that are not expected to be relieved and lead to long-lasting sequelae (eg, peripheral neuropathy that occurs after platinum-containing treatment) are allowed to be included in the study. Peripheral neuropathy must be relieved to level 2 (NCI CTCAE 5th edition); 10)According to the opinion of the investigator, any serious or uncontrolled medical disease or active infection that may increase research participation, research drug administration related risks, or damage the subject's ability to receive the treatment of the trial protocol; 11)Known human immunodeficiency virus (HIV) test positive history or known suffering from acquired immunodeficiency syndrome (AIDS); 12)Subjects who received live vaccine/attenuated vaccine within 30 days after receiving the first treatment; 13)Patients with active viral hepatitis B or C viral hepatitis. Acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV) DNA> 2000IU/ml or 104 copies/ml; hepatitis C virus (HCV) RNA> 103 copies/ml; hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive at the same time; 14)History of allergies or hypersensitivity to study drug components, and history of severe hypersensitivity to any monoclonal antibody; 15)Other researchers evaluated those who did not meet the enrollment conditions.